This study aims to examine the effects of a new 1,4-dihydropyridine derivative, VdiE-2N, on cell signaling pathways and mitochondrial events in head and neck squamous cell carcinoma (HNSCC) cells, and on a mice model of xenograft tumor growth/cell proliferation. Four HNSCC cell lines (HN13, HN12, HN6, and CAL27), HEK293 cells (human embryonic kidney 293 cells), and human oral healthy mucosa fibroblasts (OHMF) were used for in vitro assessment of cell viability (resazurin assay) and invasion capacity (modified Boyden chamber assay), and mitochondrial membrane potential (JC-1 fluorescence assay), morphology (transmission electron microscopy), and number of mitochondria (MitoTracker® imaging). SET and pDRP1 proteins were analyzed by immunofluorescence, and proteins involved in cell death/survival pathways were analyzed by Western blotting. HN12 xenograft tumors were established in the flank of Balb/c nude mice, and their characteristics and sensitivity to VdiE-2N were determined by immunohistochemistry and histology. VdiE-2N decreased cell viability in HNSCC cells (IC50 = 9.56 and 22.45 µM for HN13 and HN12 cells, respectively) more strongly than it decreased cell viability in OHMF and HEK293 cells (IC50 = 32.90 and > 50 µM, respectively). In HN13 cells, VdiE-2N dissipated mitochondrial membrane potential and altered the mitochondria size, shape, and number in a concentration-dependent manner, as well as it induced apoptosis and reduced their invasion capacity. Treatment of mice bearing xenograft tumors with VdiE-2N significantly diminished proliferation of cancer cells. Therefore, VdiE-2N induces HNSCC cell death in vitro through mitochondria-mediated apoptotic pathways and dampens tumor growth in vivo, thus supporting a potential anti-cancer effect.
Introduction
Head and neck cancer occurs at a rate of 500,000 cases per year (Conway et al., 2009 ); 90% of the cases are head and neck squamous cell carcinoma (HNSCC) and only 40-50% of the patients have an overall survival rate of five years (Leemans et al., 2011) . Risk factors for HNSCC are tobacco carcinogens, alcohol consumption, and infection by human papilloma virus type 16 and 18 (Kreimer et al., 2005) . The knowledge of tumor biology and signaling pathways of HNSCC favors the development of more effective and less toxic therapies, which thereby improve the patients' quality of life and survival, especially those who had early diagnosis (Bose et al., 2013; Feldman et al., 2015) .
Several compounds of the 1,4-dihydropyridine class (1,4-DHP) kill cells by inhibiting the P-glycoprotein pump and reversing multidrug resistance; the latter is an important factor for failure of conventional chemotherapy in many cancer types (Shekari et al., 2015; Viale et al., 2011; Voigt et al., 2007) . Other 1,4-DHPs are calcium channel blockers that display antioxidant, anticonvulsant, anti-inflammatory, anti-diabetic, and anti-tubercular pharmacological effects (Edraki et al., 2009; Nasr-Esfahani et al., 2006) . 1,4-DHPs are usually more cytotoxic towards cancer cells than towards non-cancer cells (Laupèze et al., 2001; Morshed et al., 2005) . The discovery of novel 1,4-DHP derivatives can prompt the development of new effective therapies for different pathologies, including cancer.
Mitochondria, organelles whose main function is the generation of cellular energy, are involved in failure of conventional chemotherapy in many cancer types. Mitochondria play important roles in the regulation of function and death of cancer cells, which are usually resistant to apoptosis induction. As mitochondria from malignant and healthy cells markedly differ from each other, these organelles have been considered as potential pharmacological targets in cancer (Indran et al., 2011) . Mitochondrial mutations are late events in HNSCC carcinogenesis that occur either during or after transition of the pre-neoplastic epithelium (Mithani et al., 2007) , at a rate of 21-51%; some of them are associated with characteristic tumor phenotypes (Chatterjee et al., 2006; Czarnecka et al., 2006) . SET (I2PP2A) protein accumulates in malignant brain tumors, testicular cancer, different types of hematological malignancies, and HNSCC (Christensen et al., 2011) . SET is a potent and specific inhibitor of PP2A (protein phosphatase 2A) (Li et al., 1996) , which has been associated with cell response to oxidative stress (Leopoldino et al., 2012) and regulation of myc, AKT (protein kinase B), and p53 (protein involved in cell proliferation) (Arnold and Sears, 2006; Liu et al., 2012) . SET overexpression promotes mitochondrial fission (Almeida et al., 2015) .
We have previously synthesized a new family of 1,4-DHP derivatives (Verdecia et al., 1996) . VdiE-2N ((isobutyryloxy)methyl 6-chloro-5-formyl-1,4-dihydro-2-methyl-4-(2-nitrophenyl)pyridine-3-carboxylate)) is one of the members of this family of compounds that we are currently studying. The high theoretical Log P value of suggests that this molecule is able to cross cellular and mitochondrial membranes. Indeed, other 1,4-DHP derivatives, such as cerebrocrast, gammapyrone, glutapyrone, and diethone exert different effects on mitochondria (Fernandes et al., 2003 (Fernandes et al., , 2008 . In this sense, in the present study we examined the effects of a new 1,4-DHP derivative, VdiE-2N, on the cell viability and invasion capacity, survival signaling pathways, and mitochondrial involvement in HNSCC cells in vitro, as well as on the tumor growth and cell proliferation in vivo, using the HN12 cell line and the xenograft tumor model in nude mice.
Material and methods

Human cell lines and culture conditions
The human HNSCC (head and neck squamous cell carcinoma) cell lines Cal27 (ATCC, Manassas, VA, USA), HN12 (tumorigenic and metastatic), HN13, and HN6 (Martin et al., 2014; Yeudall et al., 1994) , as well as the human embryonic kidney 293 cells (HEK293; ATCC) and primary cultures of fibroblasts derived from human oral healthy mucosa (OHMF) (approved by the Research Ethics Committee of the University of São Paulo, Campus of Ribeirão Preto, Brazil, under the protocol number 049) were cultured in Dulbecco's modified medium (Sigma-Aldrich, Munich, Germany) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA), antibiotics, and antimycotics (Sigma-Aldrich), in an incubator with 5% CO 2 and humidified atmosphere, at 37°C.
Compound
VdiE-2N ((isobutyryloxy)methyl 6-chloro-5-formyl-1,4-dihydro-2-methyl-4-(2-nitrophenyl)pyridine-3-carboxylate)) (Supplementary material, Fig S1A) was obtained as previously reported, and identified by one-and two-dimensional nuclear magnetic resonance spectroscopy (Verdecia et al., 1996) . Its purity (c.a 98.6%) was analyzed by highperformance liquid chromatography with diode-array detection or coupled to mass spectrometry, as well as by electrospray ionization time-of-flight mass spectrometry (micrOTOF-Q II -ESI-TOF mass spectrometer; Bruker Daltonics, Billerica, MA, USA) (Supplementary material, Fig S1B) , at the Natural and Synthetic Products Research Nucleus at the School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Brazil. Stock solutions of VdiE-2N were prepared in dimethyl sulfoxide (DMSO) and added to the cell culture. The vehicle control contained 0.5% DMSO.
Resazurin cell viability assay
Cell viability correlates with resazurin reduction (O'Brien et al., 2000) . Briefly, cells were cultured in 96-well plates and treated with different concentrations of VdiE-2N for 48 h. Next, the medium was replaced by Dulbecco's modified medium without phenol red (SigmaAldrich), and resazurin (0.01 mg/mL dissolved in phosphate buffered saline; Sigma-Aldrich) was added to the wells. After a 4-h incubation at 37°C, under 5% CO 2 , protected from light, fluorescence of the samples was recorded in a microplate fluorimeter under the excitation and emission wavelengths of 530/25 and 590/35 nm, respectively. Blank and positive controls were included in all experiments. Two experiments in triplicate were performed, and the IC 50 value for each cell line was calculated using the GraphPad Prism 5 software.
JC-1 assay
Mitochondrial membrane potential was estimated using the fluorescent dye JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide) assay kit. Briefly, cells were cultured in 96-well plates and treated with different VdiE-2N concentrations for 48 h. Next, JC-1 (5 µM) was added to the wells, and the plate was incubated for 30 min, at 37°C, protected from light. The cells were slowly washed twice with phosphate buffered saline pH 7.4, and fluorescence was recorded in a microplate fluorimeter. Aggregate and monomeric JC-1 were detected using the excitation-emission pairs 530/590 nm and 485/528 nm, respectively.
Transmission electron microscopy
Cells were treated with VdiE-2N for 48 h, and analyzed by transmission electron microscopy as previously described (Almeida et al., 2015) . The micrographs were obtained using a Jeol JEM 100 CXII electron microscope equipped with a digital Hamamatsu ORCA-HR camera (Ribeirão Preto Medical School, University of São Paulo, Brazil). The number of mitochondria was estimated from five images at 14 Kx, using the Image J software.
Confocal microscopy
Cells were plated on Chamber Slide™ System 4 wells (177437-Lab Tek). After 24 h, the cells were treated with 5 µM VdiE-2N for 48 h, incubated with 30 nM MitoTracker ® Red CMXRos (M-7512 Molecular probes, USA) for 15 min, at 37°C, and further fixed with absolute methanol for 10 min, at 25°C, and stained with 4',6-diamidino-2-phenylindole (DAPI) (Sigma Aldrich, USA). Cells were imaged with a Leica TCS SP8 confocal laser scanning microscope (Leica Microsystem, Germany) using the 63x objective either with 3x digital zoom or without zoom. The scale bar was defined as 25 and 50 µm for images with and without digital zoom, respectively.
Immunofluorescence analysis
Immunofluorescence staining was performed using primary antibodies against SET (sc-5655, Santa Cruz Biothecnology) and pDRP-1 (#3455, Cell Signaling). Cells were incubated with either an anti-goat DyLight™ 650 (ThermoFisher) or an anti-rabbit antibody conjugated with Alexa 488 (Invitrogen). Nuclei were stained with DAPI. Cells were imaged with a Leica TCS SP8 confocal laser scanning microscope (Leica Microsystem, Germany) using the 63x objective either with 3x digital zoom or without zoom. The scale bar was defined as 25 and 50 µm for images with and without digital zoom, respectively.
Western blotting
After a 6-h treatment with VdiE-2N, the cells were collected and the protein subcellular fractions were prepared by differential extraction using a Cell Fractionation Kit Standard (ab109719, Abcam, Cambridge, MA, EUA) and NE-PER ® Nuclear and Cytoplasmic Extraction Reagents (#78835 Thermo Fisher Scientific). Total proteins were extracted from cells using CelLytic MT (Sigma-Aldrich) with a complete cocktail of protease and phosphatase inhibitors (Sigma-Aldrich), and quantified using the Bradford protein assay (BioRad). Total proteins (10-30 µg) were submitted to electrophoresis with sodium dodecyl sulfate, using 10% and 15% polyacrylamide gels, and further transferred to a polyvinylidene difluoride membrane. The membrane was incubated overnight, at 4°C, with primary antibodies for caspase 3 (#9665), cleaved caspase 3 (#9661), caspase 8 (#9746), PARP (poly(ADP)ribose polymerase; #9532), cytochrome c (#11940), GAPDH (glyceraldehyde-3-phosphate dehydrogenase; #2118), VDAC (voltage-dependent anion channel; #4661), pVEGFR2 (phosphorylated vascular endothelial growth factor receptor 2; #3817), STAT3 (signal transducer and activator of transcription 3; #9139), pSTAT3 (phosphorylated STAT3; #9145), pDRP-1 (#3455), pAKT308 (AKT phosphorylated at Thr308; #2965), pAKT473 (AKT phosphorylated at Ser473; #4058), AKT (protein kinase B; #9272), C-myc (#5605), pERK1/2 (phosphorylated p44/42 mitogen-activated protein kinase; #4377), p21 (#2947), Rac1/2/3 (#2465) and Survivin (#2802), from Cell Signaling, and nm23-H1 (sc-343), SET (sc-5655) and β-Actin (sc47778) from Santa Cruz Biotechnology. Then, cells were washed and incubated with secondary antibodies conjugated with horseradish peroxidase, for 1 h, at room temperature. Immune complexes were detected using the ECL™ Western blotting system (GE Healthcare).
Invasion assays
Cells were incubated with VdiE-2N for 72 h, and invasion assays were performed as previously described (Sobral et al., 2014) . For each condition, five fields were photographed at 200x original magnification using a Zeiss Axiovert 40 inverted microscope and processed using the AxioVision Rel. 4.8.2 software. The cells from five fields were counted using the Image J software (Schneider et al., 2012) , and the results were expressed as the number of cells per microscopic field.
Tumorigenicity and immunohistochemistry assays
All the animal experiments were conducted following the protocol (14.1.199.53.8) approved by the ethics committee for laboratory animal use of the University of São Paulo, Campus of Ribeirão Preto, Brazil. To induce the xenograft tumor growth, 2 × 10 6 HN12 cells were injected subcutaneously into the left and right flanks of ten 8-week-old Balb/c male nude mice (Sobral et al., 2014) . After two weeks, the animals received intratumor injection of VdiE-2N (5 mg/Kg) or vehicle (DMSO) every three days. Tumor size was measured weekly using a caliper, and volume was calculated using the formula 0.5 × length × width 2 , and reported as mm 3 (Sobral et al., 2014) . At the seventeenth day of treatment, the animals were euthanized and the tumors were collected, fixed in 10% formalin, and embedded in paraffin. Five-μm sections were stained with hematoxylin and eosin for histological analysis. Three-μm sections were used for the immunohistochemical analysis of SET, Ki67, and pan-cytokeratin (pan-CTKR) as previously described (Leopoldino et al., 2012) . The following primary antibodies were used: anti-Ki67 (ab15580; Abcam), anti-pan-CTKR (ab6401; Abcam), and anti-SET. One thousand cells from three controls and three treated tumors were counted to determine the percentage of Ki67-positive cells.
Statistical analysis
Statistical analysis was performed with the aid of the GraphPad Prism 5 software, using analysis of variance (ANOVA), Dunnett or Bonferroni's post-hoc test, and Student's t-test. The significance level was set at P < 0.05.
Results
Effects of VdiE-2N on cell viability and membrane potential and number of mitochondria
We examined the cytotoxicity of VdiE-2N towards HNSCC, HEK293, and OHMF cells, using the resazurin assay. The 48-h treatment with VdiE-2N decreased viability of HNSCC cells, yielding IC 50 values of 9.56 and 22.45 µM for HN13 and HN12 cells, respectively (Table 1) . This compound decreased cell viability in OHMF and HEK293 cells less strongly, yielding IC 50 values of 32.90 and > 50 µM, respectively ( Table 2) . Viability of HN12 and HN13 cells was also evaluated after 24 h of treatment with cisplatin, a standard chemotherapy drug, which afforded IC 50 values of 20.75 and 29.41 µM, respectively (Supplementary material, Table S1 ). Both HNSCC cell lines were more sensitive to VdiE-2N than to cisplatin.
We used the mitochondrion-specific dye JC-1 to address whether VdiE-2N changes the mitochondrial membrane potential in HNSCC, HEK293, and OHMF cells. VdiE-2N dissipated the mitochondrial membrane potential in HN13 and HN12 cells in a concentration- Data are expressed as the mean ± standard error of the mean of two independent assays in triplicate (n = 6). a DMSO: 0.5% dimethyl sulfoxide (vehicle control). b CCCP: 20 μM carbonyl cyanide 3-chlorophenylhydrazone (positive control). c P < 0.05 and. d P < 0.001, treated vs. DMSO (One-way ANOVA followed by the Bonferroni's post-test).
dependent manner (Fig. 1A) , but did not significantly alter this parameter in the non-cancer cell lines HEK293 and OHMF (Fig. 1B) . This may be one of the mechanisms that mediates tumor cell death and explains the stronger cytotoxicity of VdiE-2N towards HNSCC cells than towards non-cancer cells. VdiE-2N changed the mitochondrial shape in HN13 cells, as evaluated by transmission electron microscopy (Fig. 1C) . Compared with the untreated control, HN13 cells treated with 5 and 20 µM VdiE-2N exhibited increased number of mitochondria, as demonstrated by labeling with MitoTracker® ( Fig. 1D and E) . As the balance between fission and fusion rates determines the number of mitochondria, in this study we determined the levels of phosphorylated DRP1 (pDRP1 Ser616) to examine whether VdiE-2N interferes in the mitochondrial fission process. Treatment of HN13 cells with 100 µM VdiE-2N for 6 h increased the pDRP1 levels (Fig. 1G) . The immunofluorescence microscopy analysis confirmed the increased pDRP1 levels in HN13 cells treated with 5 µM VdiE-2N for 48 h (Fig. 1F) . Together, these results suggest the occurrence of mitochondrial fission. DMSO (One-way ANOVA followed by the Bonferroni's post-test). 
VdiE-2N induces apoptotic pathways of cell death in HNSCC cells and reduces the invasion capacity of the metastatic cell line HN12
To address whether VdiE-2N (at 50 and 100 µM) induces apoptosis in HNSCC cells, we performed Western blotting analysis of PARP (poly (ADP-ribose) polymerase) activation and caspase-3/caspase-8 cleavage in HN13 and HN12 cells, and cytochrome c release from mitochondria to cytosol in HN13 cells. The 6-h treatment with VdiE-2N induced PARP activation and caspase-3/caspase-8 cleavage in both cell lines ( Fig. 2A  and B) , and decreased the level of mitochondrial cytochrome c in HN13 cells (Fig. 3C ). These findings suggest that VdiE-2N induces cell death by apoptosis with mitochondrial involvement, at least for HN13 and HN12 cells.
Next, we examined the cell invasion capacity of the metastatic cell line HN12 treated with 10 µM VdiE-2N for 72 h -this non-cytotoxic concentration (Table 1 ) was selected to avoid the interference of cell death in the assay. Compared with the control, VdiE-2N decreased the number of invading cells (Fig. 3) , suggesting that it reduces the metastatic potential of HN12 cells.
VdiE-2N influences the expression of cell survival, cell cycle, and angiogenesis signaling proteins and the c-Myc oncogene
We analyzed the expression of proteins involved in cell survival (pAKT308, pAKT473, pERK1/2, pNFKB, and pSTAT3), cell cycle (p53 and p21), and angiogenesis (pVEGFR2) signaling, as well as the expression of the c-Myc oncogene in HN13 cells treated with VdiE-2N. The 6-h treatment with 50 and 100 µM VdiE-2N lowered the levels of pAKT473, pAKT308, pSTAT3, p53, and p21 expression. At 100 µM, VdiE-2N also lowered the levels of pERK1/2 and pNFKB expression and VdiE-2N increased the levels of phosphorylated vascular endothelial growth factor receptor 2 (pVEGFR2), which may be a favorable event because the efficacy of chemotherapy depends on an efficient tumor blood flow and drug delivery (Fig. 4A) . These results indicate that VdiE-2N interfere in the three signaling pathways studied.
Next, we examined whether treatment of HN13 cells with 20 µM VdiE-2N for 48 h altered the distribution of SET and proteins involved in cell migration (Rac1/2/3), cell invasion (nm23H-1), and cell survival (NFκB and pNFκB) (Fig. 4B) . NFκB and pNFκB proteins were detected Fig. 2 . Western blotting analysis of the apoptosis markers PARP (poly(ADP-ribose) polymerase), caspase-3 (pro-caspase and cleaved forms), and caspase-8 (pro-caspase and cleaved forms) in (A) HN13 and (B) HN12 cells, and (C) mitochondrial cytochrome c release (C -cytosolic proteins; M -mitochondrial protein sub-fractions) in HN13 cells treated with VdiE-2N for 6 h. β actin was used as the loading control. GADPH (glyceraldehyde-3-phosphate dehydrogenase) and VDAC (voltage-dependent anion channel) were used as controls for cytoplasmic and mitochondrial protein sub-fractions, respectively. 
R.N. Goto et al.
European Journal of Pharmacology 819 (2018) 198-206 Fig. 4 . Western blotting analysis of the expression of cell survival, proliferation, and angiogenesis markers in HN13 cells treated with VdiE-2N. (A) Expression of pAKT473, pAKT308, pERK, pNF-κB, p53, p21, SET, STAT3, and pSTAT3 in cells treated with 50 and 100 μM VdiE-2N for 6 h; β-actin was used as the loading control protein. (B) Distribution of SET, NF-κB, pNFκB, nm23H-1, and Rac1/2/3 proteins (C -cytoplasm; N -nucleus) in cells treated with 20 μM VdiE-2N for 48 h. GADPH (glyceraldehyde-3-phosphate dehydrogenase) and fibrilarin were used as the controls for cytoplasmic and nuclear proteins, respectively. Representative images of at least 5 random fields for each condition, obtained on Leica TCS SP8 confocal laser-scanning microscope, using the 63x objective with either 3x digital zoom or without zoom. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) R.N. Goto et al. European Journal of Pharmacology 819 (2018) 198-206 predominantly in the cytoplasm, while SET protein was detected in both, cytoplasm and nucleus. The levels of nm23H-1 and Rac1/2/3 decreased in the nucleus and cytoplasm, respectively. The immunofluorescence microscopy analysis of the distribution of SET protein evidenced stronger labeling in HN13 cells treated with 20 and 50 µM VdiE-2N for 48 h, as compared with the vehicle-treated cells (Fig. 5) .
3.4. VdiE-2N reduces the volume of HN12 xenograft tumors in mice by reducing cell proliferation
Based on the in vitro results here reported, we examined whether VdiE-2N affects the tumorigenic potential of HN12 cells by using a xenograft tumor model in Balb/c nude mice. After two weeks of cell injection, mice were treated for 17 days with either 5 mg/kg VdiE-2N or the vehicle (DMSO), every three days. VdiE-2N significantly reduced the tumor volume and expression of the proliferative marker Ki67 (Fig. 6A and B) , suggesting that it diminished the cell proliferation rate.
Histological analysis did not evidence significant differences between treated and non-treated tumors: both presented well-differentiated morphology and atypical mitoses (Fig. 6C) . Immunohistochemistry analysis revealed that treated and non-treated tumors exhibited similar patterns of pan-CTKR protein staining, but treated tumors displayed increased nuclear and cytoplasmic levels of SET protein (Fig. 6D) . These results suggest that VdiE-2N treatment reduces proliferation of HN12 cells.
Discussion
Cell death evasion is the major cause of failure in cancer treatment (Fulda, 2009) . To develop new cancer therapies, scientists have sought drugs that are more cytotoxic and selective for tumor cells, such as the 1,4-DHP derivatives. In addition to the tumor-selective cytotoxicity (Morshed et al., 2005; Shekari et al., 2015) , these compounds display a wide range of pharmacological actions, such as antioxidant (Kumar et al., 2010; Mason et al., 1999) , anti-hypertensive (Shafiee et al., 2002) , anticoagulant, anti-diabetic (Ogawa et al., 2003) , anti-tubercular (Iman et al., 2015) , and anticonvulsant (Hadizadeh et al., 2013) .
Here we examined how the 1,4-DHP derivative VdiE-2N acts on four HNSCC cell lines and the non-cancer cell lines HEK293 and OHMF. VdiE-2N was more cytotoxic to HN13 cells than to the other HNSCC cell lines, which in turn were far more sensitive than HEK293 and OHMF cells. Therefore, cancer cells are more sensitive to VdiE-2N cytotoxicity than non-cancer cells.
PARP activation, cleavage of caspase-3/caspase-8, and mitochondrial cytochrome c release indicate that VdiE-2N promoted HNSCC cell death via a mitochondria-mediated pathway. Changes in the inner mitochondrial membrane permeability cause loss of mitochondrial membrane potential, mitochondrial swelling, cytochrome c release, cleavage of caspase-3/caspase-8 (Hengartner, 2000; Kroemer et al., 1998; Slee et al., 1999) , and changes in mitochondria size, shape, and number (Mancini et al., 1997; Youle and Karbowski, 2005) . The HNSCC cell lines HN13 and HN12 displayed higher mitochondrial membrane potential than the non-cancer cell lines HEK293 and OHMF, corroborating literature reports of increased mitochondrial membrane potential in tumor cells (Indran et al., 2011) . The VdiE-2N treatment decreased mitochondrial membrane potential in a concentration-dependent manner in HN13 and HN12 cells, but not in HEK293 and OHMF cells, thus suggesting that VdiE-2N exerts a more controlled effect on HNSCC cells; this finding is in line with our results on VdiE-2N cell toxicity.
Mitochondria are dynamic organelles whose number is regulated by processes of fission and fusion (Cerveny et al., 2007; Detmer and Chan, 2007) . Mitochondrial fission depends on the dynamin related protein 1 (Drp1), which anchors mitochondria at specific positions, known as constriction sites; this process removes damaged organelles and favors apoptosis through exposition to high stress levels (Youle and Karbowski, 2005; Youle and van der Bliek, 2012). The evidences that VdiE-2N increased the number of mitochondria, altered their shape (small and round), and raised the pDRP1 levels in HN13 cells, are compatible with the occurrence of mitochondrial fission. Accordingly, the literature reports that high levels of cellular stress promote intense mitochondrial fission and apoptosis (Youle and van der Bliek, 2012) .
After studying the effect of VdiE-2N on cell death, we investigated whether it interferes in cell signaling pathways, in particular those related to the SET protein. SET accumulates in HNSCC, and this event is associated with many cellular processes such as cell cycle control (Canela et al., 2003) , apoptosis (Madeira et al., 2005) , migration (Lam et al., 2013; ten Klooster et al., 2007) , DNA damage repair (Almeida et al., 2012) , and cell survival. SET also acts as oxidative stress sensor for cell death (Leopoldino et al., 2012) . Among the SET targets evaluated, VdiE-2N lowered the levels of p-AKT, ERK, STAT3, and NF-κB, which are components of cell survival pathways, and lowered the levels of p53 and p21, which participate in cell cycle control. VdiE-2N also decreased the levels of the oncogene C-myc and altered intracellular SET distribution. In HN13 control cells, SET was located in the cytoplasm and nucleus, mainly in the perinuclear region; in VdiE-2N-treated cells, SET was predominantly located in the cytoplasm.
SET acts as inhibitor of the tumor suppressor nm23-H1 (Fan et al., 2003) , which amplifies the Rac-1 signaling. Rac1-SET interaction in the cytoplasm promotes cell migration (ten Klooster et al., 2007) . SET and nm23-H1 bind to each other and translocate to the nucleus, where nm23-H1 acts as DNAse. The presence of nm23-H1 in the nucleus, in turn, is associated with resistance to cell death in HNSCC (Kim et al., 2011) . VdiE-2N lowered the cytoplasmic level of Rac1/2/3 and the nuclear level of nm23-H1 in HN13 cells, suggesting that this compound is able to reduce both cell migration and invasion capacities.
Finally, VdiE-2N exerted antitumor effect in a xenograft tumor model using Balb/c nude mouse and HN12 cells, as evidenced by suppression of tumor growth and cell proliferation. These in vivo results are consistent with the in vitro inhibition of cell proliferation and invasion capacity. The fact that xenograft tumors from VdiE-2N-treated mice exhibited increased nuclear and cytoplasmic levels of SET may be a favorable event, because SET suppresses metastasis and regulates invasion, and decreased SET levels may trigger aggressive behavior in HNSCC (Sobral et al., 2014) . It is worth to notice that the presence of the formyl moiety at C-5 can favor unspecific toxicity of VdiE-2N, due to the well-known general toxic effects of aldehydes (Feron et al., 1991; LoPachin and Gavin, 2014) . However, the consistency of the in vitro and in vivo anticancer effect here reported, associated with the novelty of its chemical structure, point out to VdiE-2N as a lead compound for the design of new, more selective, and less toxic anticancer agents.
Conclusion
VdiE-2N is cytotoxic towards HNSCC cell lines, induces cell death via mitochondria-mediated apoptosis, and decreases tumor growth in vivo. Thus, VdiE-2N is a potential anti-cancer agent.
